SWOG S2101

Primary Category:

Treatment Protocols

Disease Category:

Melanoma, Metastatic Melanoma, Skin


Temporarily Closed

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study


S2101 is temporarily closed to accrual on June 7, 2023,  effective at 12:00pm Pacific Time.